oncology
Clinical Summary
A 5-year randomised, placebo-controlled trial of pembrolizumab found a 38% reduction in death vs placebo.
Clinical Summary
However, it's not yet clear whether a new three-phase screening intervention, which incorporates PSA test, a four-kallikrein panel, and MRI, will reduce prostate cancer mortality.